Recruiting NCT07473648
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Electroconvulsive Therapy, Magnetic Seizure Therapy.
- Who it may be relevant to
- Registry conditions: Electroconvulsive Therapy, Major Depressive Disorder, Magnetic Seizure Therapy. Basic parameters: 12 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).
Interventions
- Device Electroconvulsive Therapy
Electroconvulsive therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions. - Device Magnetic Seizure Therapy
Magnetic seizure therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.
Primary outcome measures
- Change in Hamilton Depression Rating Scale Total Score. [Time frame: Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.]
- Change in heart rate variability (HRV) parameters derived from electrocardiogram (ECG). [Time frame: Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.]
- Change in Hamilton Anxiety Rating Scale Total Score. [Time frame: Baseline, immediately after each treatment session during the intervention period, and 6 months after the end of intervention.]
- Change in the Overall Composite Score of the MATRICS Consensus Cognitive Battery. [Time frame: Baseline and after the completion of the last session (an average of 2 weeks).]
Secondary outcome measures (1)
- Change in resting-state brain activity in specific brain regions. [Time frame: Baseline and after the completion of the last session (an average of 2 weeks).]
Eligibility criteria
Inclusion criteria
- Aged 12-80 years;
- Diagnosis confirmed by two psychiatrists per DSM-5;
- Stable medication regimen pre-enrollment;
- Indicated for neuromodulation OR with visual field defects.
Exclusion criteria
- Major systemic diseases;
- Prior neuromodulation within 3 months;
- Pregnancy or potential pregnancy;
- Metal implants or claustrophobia.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Health services research
Study locations
China · 1 center
- Anhui Medical University — Hefei
Publications
- Hirano J, Takamiya A, Yamagata B, Hotta S, Miyasaka Y, Pu S, Iwanami A, Uchida H, Mimura M. Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. J Psychiatr Res. 2017 Aug;91:26-35. doi: 10.1016/j.jpsychires.2017.02.018. Epub 2017 Feb 22. PMID 28292650
- Downey D, Brigadoi S, Trevithick L, Elliott R, Elwell C, McAllister-Williams RH, Anderson IM. Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy. J Psychopharmacol. 2019 Aug;33(8):1003-1014. doi: 10.1177/0269881119858313. Epub 2019 Jun 25. PMID 31237182
- Chhoa KH, Chiang SK, Ong KY, Yong CK, Ng BZ, Othman SZ, McIntyre RS, Choi J, Cha J, Ho RC, Chee KY. Changes in Cerebral Hemodynamic Among Patients With Schizophrenia or Bipolar Disorder Receiving Electroconvulsive Therapy: A Task-Related Functional Near-Infrared Spectroscopy Study. J ECT. 2026 Mar 1;42(1):11-18. doi: 10.1097/YCT.0000000000001110. Epub 2025 Jan 24. PMID 39853313
- Wang W, Lu Y, Mi GL, Li XJ, Zhang DN, Qi SF. Cognitive preservation advantage and efficacy balance of magnetic seizure therapy in adolescent Major Depressive Disorder: a randomized controlled trial revealing efficacy cognition decoupling phenomenon. Riv Psichiatr. 2025 Sep-Oct;60(5):196-201. doi: 10.1708/4583.45901. PMID 41070420
- Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003 Oct;28(10):1852-65. doi: 10.1038/sj.npp.1300229. PMID 12865903
- Jiang J, Zhang C, Li C, Chen Z, Cao X, Wang H, Li W, Wang J. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev. 2021 Jun 16;6(6):CD013528. doi: 10.1002/14651858.CD013528.pub2. PMID 34131914
- Deng ZD, Luber B, McClintock SM, Weiner RD, Husain MM, Lisanby SH. Clinical Outcomes of Magnetic Seizure Therapy vs Electroconvulsive Therapy for Major Depressive Episode: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Mar 1;81(3):240-249. doi: 10.1001/jamapsychiatry.2023.4599. PMID 38055283
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024 May 18;403(10440):2133-2161. PMID 38642570
Identifiers
NCT: NCT07473648 · AHMU-MST/ECT-MDD